<DOC>
	<DOCNO>NCT00453297</DOCNO>
	<brief_summary>This Phase I trial healthy , post-menopausal woman design double-blind , placebo-controlled , randomize , ascend single-dose safety trial . MF101 administer single oral dose total 32 enrolled subject age 40-65 year . Eight subject assign four cohort . Within cohort , six subject randomize receive MF101 two subject receive placebo . MF101 dose incrementally escalate stop criterion reach . If stop criterion reach fourth cohort receives dose , next cohort may receive dose dose administer cohort exhibit symptom MF101 toxicity next low dose group .</brief_summary>
	<brief_title>Phase I Study Evaluate Safety Efficacy MF101 Well Pharmacokinetics Its Key Active Components</brief_title>
	<detailed_description>The primary goal study identify high safe oral dose MF101 well tolerate human . Secondary goal include : characterize clinical symptom MF101 toxicity healthy subject evaluate dose-dependent pharmacokinetics key MF101 active component single oral dose .</detailed_description>
	<criteria>Postmenopausal female , good health 40 65 year age . Normal body mass index equal great 18 great 36 Postmenopausal define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 30 mlU/ml 6 week postsurgical bilateral oophorectomy without hysterectomy , hysterectomy FSH level &gt; 30 mlU/ml . Ability comprehend willingness sign inform consent form . Ability willingness understand follow study procedure . Clinical laboratory evaluation within reference range test laboratory , unless regard clinically significant Principle Investigator . Must mammogram within last 9 month . Negative urine test select drug abuse screen checkin study unit . Negative hepatitis panel ( include HBsAg antiHCV ) , HIV antibody screen . No chronic medication take . Must primary care physician . History clinical manifestation significant metabolic , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , hepatic , gall bladder , renal , urological , psychiatric disorder . Dyslipidemia History abnormal renal function , uncontrolled hypertension , malignancy . History breast , uterine ovarian cancer melanoma . History brain aneurism ischemic event . Febrile disease Autoimmune disorder lupus erythematosis , multiple sclerosis rheumatoid arthritis . Severe vasomotor symptom define &gt; 7/day &gt; 50/week . Abnormal mammogram breast examination within last 9 month suggestive cancer . Abnormal Pap smear pelvic examination within last 9 month suggestive cancer . Doublewall endometrial thickness exceed 5 mm measure transvaginal ultrasound . Unexplained abnormal uterine bleeding within six month enrollment . Pregnancy lactate . History deep vein thrombosis pulmonary embolism require anticoagulation . History hypersensitivity allergy drug compound , include constituent MF101 unless approve Principle Investigator . History presence clinically significant abnormal ECG ( QTcB &gt; 450msec screen variation QTcB &gt; 30msec screening ) . Likely need medication study include contraceptive . History alcoholism drug addiction within 1 year prior study entry ( i.e. , prior checkin Day1 ) . Use tobacco product ( include cigarette , pipe , cigar , chew , nicotine patch , nicotine gum ) within 6 month prior study entry . Receipt investigational drug within 60 day prior study entry . Use prescription medication know possibly effective treatment hot flash within three month enrollment oral transdermal drug , within 6 month enrollment implant injected drug . Use raloxifene , tamoxifen aromatase inhibitor within three month enrollment . Use prescription medication alcoholcontaining products/medications within 14 day prior study entry . Use overthecounter , nonprescription preparation , within 7 day prior study entry . Use caffeinecontaining products/medications within 72 hour prior study entry . Donation blood within 6 week prior study entry plasma within 2 week prior screen . Receipt blood product within 2 month prior study entry . Any condition prior therapy , opinion Investigator , would make subject unsuitable study .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Bionovo</keyword>
	<keyword>MF101</keyword>
	<keyword>Herbs</keyword>
	<keyword>The primary goal study identify high safe oral dose MF101 well tolerate human .</keyword>
</DOC>